source
- Carvykti shows 5-year survival in half of multiple myeloma patients in Phase 2 studyJohnson & Johnson and Legend Biotech reported that 10 of the 20 multiple myeloma patients treated with a single dose of Carvykti remained alive after a median follow‑up of 60.7 months, representing…
- FDA approves Mirum's Atebrioz for ultra-rare disease that hardens muscle and connective tissueThe U.S. Food and Drug Administration has granted approval for Mirum Pharmaceuticals' new therapy for an ultra-rare genetic disorder that causes muscle and connective tissue to turn into bone. The…